New Switchable CAR-T Therapy Enters Phase 1 Trial for Advanced Breast Cancer

New switchable CAR-T therapy enters phase 1 trial for advanced breast cancer

The Calibr-Skaggs Institute for Innovative Medicines, the drug development division of Scripps Research, today announced a milestone in cancer treatment with the dosing of the first patient in a phase 1 trial (NCT06878248) evaluating CLBR001 + ABBV-461, a modular, switchable chimeric antigen receptor T cell (sCAR-T) therapy in patients with advanced or metastatic breast cancer who have no suitable treatment options.

Calibr-Skaggs Administers First Patient with Switchable CAR-T Cell Therapy

Revolutionizing Solid Tumor Treatment: The Dawn of Switchable CAR-T Therapy in Advanced Breast Cancer In a groundbreaking advancement poised to reshape cancer therapy, researchers at the Calibr-Skaggs Institute for Innovative Medicines, part of the renowned Scripps Research, have initiated a first-in-human clinical trial evaluating a novel switchable chimeric antigen receptor T cell (sCAR-T) therapy for advanced breast cancer. This Phase 1 dose-…